Literature DB >> 9272099

Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance.

B Ahrén1, H Larsson, J J Holst.   

Abstract

OBJECTIVE: The gastrointestinal hormones, gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), are both released from the gut after oral glucose ingestion and stimulate insulin secretion. This study examined the release of these hormones in subjects with impaired glucose tolerance (IGT), which precedes the development of non-insulin-dependent diabetes. DESIGN AND METHODS: Six postmenopausal women with IGT, aged 59 years, underwent a 75 g oral glucose tolerance test and plasma levels of GIP and GLP-1 were determined regularly during the following 2 h. The results were compared with those in seven age- and weight-matched women with normal glucose tolerance (NGT).
RESULTS: Basal plasma levels of GIP and GLP-1 were not different between the groups. In response to the oral glucose ingestion, plasma levels of both GIP and GLP-1 increased in both groups. The plasma GIP increase after glucose ingestion was, however, reduced in women with IGT. Thus, the GIP response as determined as the area under the curve for the 60 min after oral glucose was 34.8 +/- 3.2 pmol/l per min in women with IGT versus 56.4 +/- 7.8 pmol/l per min in those with NGT (P = 0.021). In contrast, the GLP-1 response to oral glucose was not different between the groups. By definition, the glucose response to oral glucose was markedly increased in women with IGT, and the insulin response during the second hour after glucose ingestion was exaggerated.
CONCLUSIONS: The GIP response to oral glucose is impaired in postmenopausal women with IGT, whereas the plasma GLP-1 response is not affected.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9272099     DOI: 10.1530/eje.0.1370127

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  22 in total

Review 1.  The role of incretin therapy at different stages of diabetes.

Authors:  Simona Cernea
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 2.  Treatment of prediabetes.

Authors:  Mustafa Kanat; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  World J Diabetes       Date:  2015-09-25

Review 3.  Physiology of incretins in health and disease.

Authors:  Carolyn F Deacon; Bo Ahrén
Journal:  Rev Diabet Stud       Date:  2011-11-10

4.  Postprandial Insulin Response and Clearance Among Black and White Women: The Federal Women's Study.

Authors:  Stephanie T Chung; Mirella Galvan-De La Cruz; Paola C Aldana; Lilian S Mabundo; Christopher W DuBose; Anthony U Onuzuruike; Mary Walter; Ahmed M Gharib; Amber B Courville; Arthur S Sherman; Anne E Sumner
Journal:  J Clin Endocrinol Metab       Date:  2019-01-01       Impact factor: 5.958

Review 5.  Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.

Authors:  A Zarrinpar; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2012-10-11       Impact factor: 8.171

Review 6.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

Review 7.  Gut peptides and type 2 diabetes mellitus treatment.

Authors:  Bo Ahrén
Journal:  Curr Diab Rep       Date:  2003-10       Impact factor: 4.810

8.  Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

Authors:  Jerry R Greenfield; I Sadaf Farooqi; Julia M Keogh; Elana Henning; Abdella M Habib; Anthea Blackwood; Frank Reimann; Jens J Holst; Fiona M Gribble
Journal:  Am J Clin Nutr       Date:  2008-12-03       Impact factor: 7.045

9.  Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action.

Authors:  K Faerch; A Vaag; J J Holst; C Glümer; O Pedersen; K Borch-Johnsen
Journal:  Diabetologia       Date:  2008-03-04       Impact factor: 10.122

10.  Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.

Authors:  Victor A Gault; Peter R Flatt; Clifford J Bailey; Patrick Harriott; Brett Greer; Mark H Mooney; Finbarr P M O'harte
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.